Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/8101
Type: | Journal article |
Title: | Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate |
Author: | Nand, Swaran L. Webster, M. A. Baber, Rodney J. Heller, G. Z. |
Citation: | Climacteric, 1998; 1(3):211-218 |
Publisher: | Parthenon Pub. |
Issue Date: | 1998 |
ISSN: | 1369-7137 |
Statement of Responsibility: | S. L. Nand, M. A. Webster, R. Babert, G. Z. Heller for the Ogen/Provera Study Group |
Abstract: | Objectives: To establish the optimum oral daily dose of micronized medroxyprogesterone acetate (MPA), given in combination with 1.25 mg of estrone sulfate for menopausal symptom control. Methods: This multicenter, randomized, double-blind study was conducted on 568 postmenopausal women who were randomized to take estrone sulfate 1.25 mg daily with 2.5, 5.0 or 10 mg of MPA daily for 2 years. The number of vasomotor symptoms and the severity of mood swings, lethargy, vaginal dryness and loss of libido as well as side-effects were recorded in a diary. Blood pressure and weight were recorded at each 3-month visit. Results: Vasomotor symptoms were reported by approximately 80% of subjects at month 1, 23% at month 3 but only 9% by month 24. Mood swings, lethargy and vaginal dryness improved rapidly in the initial 3 months of therapy. Decrease in libido had a slower response to therapy in all three treatment groups. Breast tenderness was the commonest side-effect with 22% of subjects complaining of this in the first 3 months of therapy, dropping to 13% by 6 months. Headache, depression, nausea, bloating and irritability showed a similar pattern of decline. There was no significant difference in the rate of decrease in menopausal symptoms or reported side-effects between the three treatment groups. There was a small but significant (p < 0.001) decrease in systolic and diastolic blood pressure over the study period. Conclusions: All three treatment regimens provide adequate symptom control. Side-effects decreased markedly after the first 3 months, with no significant difference between the treatment groups. |
Keywords: | Menopause; Estrone Sulfate; Medroxyprogesterone Acetate |
Appears in Collections: | Obstetrics and Gynaecology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.